Concordance of PD‐1 and PD‐L1 (B7‐H1) in paired primary and metastatic clear cell renal cell carcinoma

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Brian I. Rini et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma

(2019) Xingming Zhang et al.   BMC CANCER

Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers

(2018) Sabina Signoretti et al.   JOURNAL OF CLINICAL ONCOLOGY

The Identification of Immunological Biomarkers in Kidney Cancers

(2018) Antonio Lopez-Beltran et al.   Frontiers in Oncology

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation

(2015) R. W. Joseph et al.   Cancer Immunology Research

Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma

(2015) M. Callea et al.   Cancer Immunology Research

Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type

(2014) Z. Gatalica et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases

(2014) L.B. Jilaveanu et al.   Journal of Cancer